Biomarkers of response and resistance to DNA repair targeted therapies

Clinical Cancer Research

Volumn 22, Issue 23, 2016, Pages 5651-5660

  Stover, Elizabeth H ^a   Konstantinopoulos, Panagiotis A ^a   Matulonis, Ursula A ^a   Swisher, Elizabeth M ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; ATM PROTEIN; ATR PROTEIN; AZD 0156; AZD 6738; BIOLOGICAL MARKER; CC 115; CC 122; GDC 0575; LUCANTHONE; METHOXYAMINE; MK 8776; MSC 2490484A; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; NU 7026; NU 7441; OLAPARIB; PF 00477736; PREXASERTIB; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; RUCAPARIB; SCH 900776; TALAZOPARIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; VX 970; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADVANCED CANCER; BREAST CANCER; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPAIR; DRUG RESPONSE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENE STRUCTURE; HOMOLOGOUS RECOMBINATION; HUMAN; LYMPHOMA; MOLECULARLY TARGETED THERAPY; OVARY CANCER; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMALL CELL LUNG CANCER; SOLID TUMOR; TUMOR RESISTANCE; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; MUTATION; NEOPLASM;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; MUTATION; NEOPLASMS;

EID: 85006275578     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0247     Document Type: Review

References (93)

1. Dietlein F, Thelen L, Reinhardt HC Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet 2014; 30:326-39.
2. Velic D, Couturier AM, Ferreira M.T., Rodrigue A., Poirier GG, Fleury F, et al. DNA damage signalling and repair inhibitors: the long-sought-after achilles' heel of cancer. Biomolecules 2015; 5:3204-59.
3. O'Connor MJ. Targeting the DNA damage response in cancer. Mol Cell 2015; 60:547-60.
4. Ceccaldi R, Rondinelli B, D'Andrea AD. Repair pathway choices and consequences at the double-strand break. Trends Cell Biol 2016; 26: 52-64.
5. McLornan DP, List A, Mufti GJ Applying synthetic lethality for the selective targeting of cancer. N Engl J Med 2014; 371:1725-35.
6. Lord CJ, Tutt AN, Ashworth A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev Med 2015; 66:455-70.
7. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609-15.
8. Pennington KP, Walsh T, Harrell M.I., Lee MK, Pennil CC, Rendi MH, et al Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014; 20:764-75.
9. Patch AM, Christie EL, Etemadmoghadam D, Garsed D.W., George J., Fereday S, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 2015; 521:489-94.
10. Konstantinopoulos PA, Ceccaldi R, Shapiro G.I., D'Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov 2015; 5:1137-54.
11. Guillotin D, Martin SA Exploiting DNA mismatch repair deficiency as a therapeutic strategy. Exp Cell Res 2014; 329:110-5.
12. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507: 315-22.
13. Jacobsen C, Honecker F. Cisplatin resistance in germ cell tumours: models and mechanisms. Andrology 2015; 3:111-21.
14. Koberle B, Masters JR, Hartley J.A., Wood RD. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testiculargerm cell tumours. Curr Biol 1999; 9:273-6.
15. Van Allen E.M., Mouw KW, Kim P, Iyer G., Wagle N, Al-Ahmadie H, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscleinvasive urothelial carcinoma. Cancer Discov 2014; 4:1140-53.
16. Maede Y, Shimizu H, Fukushima T., Kogame T, Nakamura T, Miki T., et al. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel. Mol Cancer Ther 2014; 13:214-20.
17. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera J.M., et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015; 161:1215-28.
18. Waddell N, Pajic M, Patch A.M., Chang DK, Kassahn KS, Bailey P, et al Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015; 518:495-501.
19. Farmer H, McCabe N, Lord C.J., Tutt AN, Johnson DA, Richardson TB, et al Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21.
20. Bryant HE, Schultz N, Thomas H.D., Parker KM, Flower D, Lopez E, et al Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434:913-7.
21. Scott CL, Swisher EM, Kaufmann SH Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol 2015; 33:1397-406.
22. Ledermann JA, El-Khouly F. PARP inhibitors in ovarian cancer: clinical evidence for informed treatment decisions. Br J Cancer 2015; 113:S10-6.
23. Liu JF, Konstantinopoulos PA, Matulonis UA PARP inhibitors in ovarian cancer: current status and future promise. Gynecol Oncol 2014; 133:362-9.
24. Matulonis UA, Harter P, Gourley C., Friedlander M, Vergote I, Rustin G., et al. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for postprogression poly(adenosine diphosphate ribose) poly-merase inhibitor therapy. Cancer 2016; 122:1844-52.
25. Swisher EM, Sakai W, Karlan B.Y., Wurz K., Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008; 68:2581-6.
26. Norquist B, Wurz KA, Pennil C.C., Garcia R., Gross J, Sakai W, et al Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011; 29:3008-15.
27. Gelmon KA, Tischkowitz M, Mackay H., Swenerton K, Robidoux A, Tonkin K., et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12: 852-61.
28. Ceccaldi R, O'Connor KW, Mouw KW, Li A.Y., Matulonis UA, D'Andrea AD, et al. A unique subset ofepithelial ovarian cancers with platinumsensitivity and PARP inhibitor resistance. Cancer Res 2015; 75:628-34.
29. Bunting SF, Callen E, Kozak M.L., Kim JM, Wong N, Lopez-Contreras AJ, et al. BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. Mol Cell 2012; 46:125-35.
30. Xu G, Chapman JR, Brandsma I, Yuan J., Mistrik M, Bouwman P, et al REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature 2015; 521:541-4.
31. Mateo J, Carreira S, Sandhu S., Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparibinmetastatic prostate cancer. N Engl J Med 2015; 373:1697-708.
32. Alexandrov LB, Stratton MR Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev 2014; 24:52-60.
33. Helleday T, Eshtad S, Nik-Zainal S. Mechanisms underlying mutational signatures in human cancers. Nat Rev Genet 2014; 15:585-98.
34. Watkins JA, Irshad S, Grigoriadis A., Tutt AN. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res 2014; 16:211.
35. Alexandrov LB, Nik-Zainal S, Wedge D.C., Aparicio SA, Behjati S, Biankin AV, et al Signatures of mutational processes in human cancer. Nature 2013; 500:415-21.
36. Wang ZC, Birkbak NJ, Culhane A.C., Drapkin R., Fatima A, Tian R, et al Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res 2012; 18:5806-15.
37. Birkbak NJ, Wang ZC, Kim J.Y., Eklund AC, Li Q, Tian R, et al Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2012; 2:366-75.
38. Popova T, Manie E, Rieunier G., Caux-Moncoutier V, Tirapo C, Dubois T., et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 2012; 72: 5454-62.
39. Marquard AM, Eklund AC, Joshi T, Krzystanek M., Favero F, Wang ZC, et al Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res 2015; 3:9.
40. Swisher EM, Lin KK, Oza A.M., Scott CL, Giordano H, Sun J, et al Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. In press.
41. Telli ML, Timms KM, Reid J, Hennessy B., Mills GB, Jensen KC, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 2016; 22:3764-73.
42. Mirza MR, Monk BJ, Herrstedt J, Oza A.M., Mahner S., Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016 Oct 7. [Epub ahead of print].
43. Konstantinopoulos PA, Spentzos D, Karlan B.Y., Taniguchi T., Fountzilas E, Francoeur N, et al Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010; 28:3555-61.
44. Kang J, D'Andrea AD, Kozono D. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J Natl Cancer Inst 2012; 104:670-81.
45. Pitroda SP, Pashtan IM, Logan H.L., Budke B., Darga TE, Weichselbaum RR, et al. DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy. Sci Transl Med 2014; 6:229ra42.
46. Lloyd KL, Cree IA, Savage RS Prediction of resistance to chemotherapy in ovarian cancer: a systematic review. BMC Cancer 2015; 15:117.
47. Moskwa P, Buffa FM, Pan Y, Panchakshari R., Gottipati P, Muschel RJ, et al miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 2011; 41:210-20.
48. Vollebergh MA, Jonkers J, Linn SC Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. Cell Mol Life Sci 2012; 69:223-45.
49. Redon CE, Nakamura AJ, Zhang Y.W., Ji JJ, Bonner WM, Kinders RJ, et al Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res 2010; 16:4532-42.
50. Naipal KA, Verkaik NS, Ameziane N, van Deurzen C.H., Ter Brugge P, Meijers M, et al Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment. Clin Cancer Res 2014; 20:4816-26.
51. Mukhopadhyay A, Elattar A, Cerbinskaite A., Wilkinson SJ, Drew Y, Kyle S, et al Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res 2010; 16:2344-51.
52. Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J, et al. Amarker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010; 16:6159-68.
53. Willers H, Gheorghiu L, Liu Q., Efstathiou JA, Wirth LJ, Krause M, et al DNA damage response assessmentsinhuman tumorsamplesprovide functional biomarkers of radiosensitivity. Semin Radiat Oncol 2015; 25:237-50.
54. Furuta T, Takemura H, Liao Z.Y., Aune GJ, Redon C, Sedelnikova OA, et al Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 2003; 278:20303-12.
55. LoRusso PM, Li J, Burger A., Heilbrun LK, Sausville EA, Boerner SA, et al Phase I safety, pharmacokinetic, and pharmacodynamic study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors. Clin Cancer Res 2016; 22:3227-37.
56. Drew Y, Ledermann J, Hall G., Rea D, Glasspool R, Highley M., et al. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer 2016; 114:723-30.
57. Plummer R, Jones C, Middleton M., Wilson R, Evans J, Olsen A., et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008; 14:7917-23.
58. Gottipati P, Vischioni B, Schultz N., Solomons J, Bryant HE, Djureinovic T, et al Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 2010; 70:5389-98.
59. Michels J, Vitale I, Galluzzi L., Adam J, Olaussen KA, Kepp O, et al Cisplatin resistance associated with PARP hyperactivation. Cancer Res 2013; 73: 2271-80.
60. Zaremba T, Thomas HD, Cole M, Coulthard S.A., Plummer ER, Curtin NJ. Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers. Biochem J 2011; 436:671-9.
61. Schlacher K, Christ N, Siaud N., Egashira A, Wu H, Jasin M. Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell 2011; 145:529-42.
62. Kais Z, Rondinelli B, Holmes A., O'Leary C, Kozono D, D'Andrea AD, Ceccaldi R. FANCD2 maintains fork stability in BRCA1/2-deficient tumors and promotes alternative end-joining DNA repair. Cell Rep 2016; 15:2488-99.
63. Lavin MF, Kozlov S, Gatei M., Kijas AW. ATM-Dependent phosphorylation of all three members of the MRN complex: from sensor to adaptor. Biomolecules 2015; 5:2877-902.
64. Nam EA, Cortez D. ATR signalling: more than meetingat the fork. Biochem J 2011; 436:527-36.
65. Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 2013; 14:197-210.
66. Weber AM, Ryan AJ ATM and ATR as therapeutic targets in cancer. Pharmacol Ther 2015; 149:124-38.
67. Hall AB, Newsome D, Wang Y., Boucher DM, Eustace B, Gu Y, et al Potentiationoftumor responsestoDNA damaging therapybythe selective ATR inhibitor VX-970. Oncotarget 2014; 5:5674-85.
68. Mohni KN, Kavanaugh GM, Cortez D. ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency. Cancer Res 2014; 74: 2835-45.
69. Toledo LI, Murga M, Zur R., Soria R, Rodriguez A, Martinez S., et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol 2011; 18: 721-7.
70. Reaper PM, Griffiths MR, Long J.M., Charrier JD, Maccormick S, Charlton PA, et al Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 2011; 7:428-30.
71. Murga M, Campaner S, Lopez-Contreras AJ, Toledo L.I., Soria R., Montana MF, et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol 2011; 18:1331-5.
72. Schoppy DW, Ragland RL, Gilad O, Shastri N., Peters AA, Murga M, et al. Oncogenic stress sensitizes murine cancerstohypomorphic suppression of ATR. J Clin Invest 2012; 122:241-52.
73. Flynn RL, Cox KE, Jeitany M, Wakimoto H., Bryll AR, Ganem NJ, et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 2015; 347:273-7.
74. Davidson D, Amrein L, Panasci L., Aloyz R. Small molecules, inhibitors of DNA-PK, targeting DNA repair, and beyond. Front Pharmacol 2013; 4:5.
75. Goodwin JF, Knudsen KE Beyond DNA repair: DNA-PK function in cancer. Cancer Discov 2014; 4:1126-39.
76. Mortensen DS, Perrin-Ninkovic SM, Shevlin G., Elsner J, Zhao J, Whitefield B., et al. Optimization of aseries of triazole containing mammalian target of rapamycin (mTOR) kinase inhibitors and the discovery of CC-115. J Med Chem 2015; 58:5599-608.
77. Nutley BP, Smith NF, Hayes A, Kelland L.R., Brunton L., Golding BT, et al. Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. Br J Cancer 2005; 93:1011-8.
78. Zhao Y, Thomas HD, Batey M.A., Cowell IG, Richardson CJ, Griffin RJ, et al Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 2006; 66:5354-62.
79. Riabinska A, Daheim M, Herter-Sprie GS, Winkler J., Fritz C, Hallek M, et al Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med 2013; 5:189ra78.
80. Gavande NS, VanderVere-Carozza PS, Hinshaw H.D., Jalal SI, Sears CR, Pawelczak KS, et al DNA repair targeted therapy: the pastorfuture of cancer treatment? Pharmacol Ther 2016; 160:65-83.
81. Bajrami I, Frankum JR, Konde A, Miller R.E., Rehman FL, Brough R, et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res 2014; 74: 287-97.
82. Joshi PM, Sutor SL, Huntoon C.J., Karnitz LM. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly (ADP-ribose) polymerase inhibitors. J Biol Chem 2014; 289:9247-53.
83. Hirai H, Iwasawa Y, Okada M., Arai T, Nishibata T, Kobayashi M., et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009; 8:2992-3000.
84. Alix-Panabieres C., Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 2016; 6:479-91.
85. Bignami M, Casorelli I, Karran P. Mismatch repair and response to DNA-damaging antitumour therapies. Eur J Cancer 2003; 39:2142-9.
86. Liu JF, Barry WT, Birrer M, Lee J.M., Buckanovich RJ, Fleming GF, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014; 15:1207-14.
87. Ibrahim YH, Garcia-Garcia C, Serra V., He L, Torres-Lockhart K, Prat A, et al PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2012; 2:1036-47.
88. Juvekar A, Burga LN, Hu H, Lunsford E.P., Ibrahim YH, Balmana J, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2012; 2:1048-63.
89. Le DT, Uram JN, Wang H, Bartlett B.R., Kemberling H., Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372:2509-20.
90. Howitt BE, Shukla SA, Sholl L.M., Ritterhouse LL, Watkins JC, Rodig S, et al Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol 2015; 1:1319-23.
91. Strickland KC, Howitt BE, Shukla S.A., Rodig S., Ritterhouse LL, Liu JF, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 2016; 7:13587-98.
92. Bicknell DC, Kaklamanis L, Hampson R., Bodmer WF, Karran P. Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas. Curr Biol 1996; 6:1695-7.
93. Lheureux S, Bowering V, Karakasis K., Oza AM. Safety evaluation of olaparib for treating ovarian cancer. Expert Opin Drug Saf 2015; 14:1305-16.